NASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News $21.67 -0.29 (-1.32%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$21.60▼$22.4550-Day Range$15.73▼$23.6052-Week Range$15.23▼$24.58Volume534,752 shsAverage Volume470,374 shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target$45.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Crinetics Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside110.0% Upside$45.50 Price TargetShort InterestHealthy6.37% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment1.08Based on 9 Articles This WeekInsider TradingSelling Shares$132,624 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.41) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector215th out of 988 stocksPharmaceutical Preparations Industry95th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.50, Crinetics Pharmaceuticals has a forecasted upside of 110.0% from its current price of $21.67.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.37% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently decreased by 18.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 2.8 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Crinetics Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold 20.24% more of their company's stock than they have bought. Specifically, they have bought $110,300.00 in company stock and sold $132,624.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions95.64% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.41) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Crinetics Pharmaceuticals (NASDAQ:CRNX) StockCrinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.Read More Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Stock News HeadlinesJune 10, 2023 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Coelho Rogerio Vivaldi Acquires 5,000 SharesJune 9, 2023 | finance.yahoo.comCrinetics to Highlight Broad Pipeline at ENDO 2023June 10, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. June 8, 2023 | markets.businessinsider.comWhere Crinetics Pharmaceuticals Stands With AnalystsJune 5, 2023 | markets.businessinsider.comCrinetics Pharmaceuticals (CRNX) Receives a Buy from Piper SandlerMay 25, 2023 | seekingalpha.comCrinetics Pharmaceuticals And Its Value Proposition In AcromegalyMay 22, 2023 | americanbankingnews.comBrokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $44.20May 17, 2023 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. Forecasted to Post FY2023 Earnings of ($3.62) Per Share (NASDAQ:CRNX)June 10, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 15, 2023 | markets.businessinsider.comCrinetics Pharmaceuticals (CRNX) Gets a Buy from Piper SandlerMay 9, 2023 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Given New $43.00 Price Target at JMP SecuritiesMay 9, 2023 | americanbankingnews.comFY2027 Earnings Estimate for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Issued By HC WainwrightMay 7, 2023 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year High Following Analyst UpgradeMay 6, 2023 | finance.yahoo.comCrinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 5, 2023 | msn.comJMP Securities Maintains Crinetics Pharmaceuticals (CRNX) Outperform RecommendationMay 5, 2023 | msn.comHC Wainwright & Co. Reiterates Crinetics Pharmaceuticals (CRNX) Buy RecommendationMay 5, 2023 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 5, 2023 | markets.businessinsider.comCrinetics Pharmaceuticals (CRNX) Receives a Buy from H.C. WainwrightMay 5, 2023 | finance.yahoo.comCrinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue EstimatesMay 4, 2023 | finance.yahoo.comCrinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 24, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Crinetics PharmaceuticalsApril 24, 2023 | cnbc.comPiper Sandler says buy this under-the-radar pharmaceutical stock poised to more than triple from hereApril 24, 2023 | msn.comPiper Sandler Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Overweight RecommendationApril 24, 2023 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Buy" by AnalystsApril 24, 2023 | americanbankingnews.comPiper Sandler Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)April 16, 2023 | finance.yahoo.comThe past year for Crinetics Pharmaceuticals (NASDAQ:CRNX) investors has not been profitableApril 7, 2023 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 8,212 SharesSee More Headlines CRNX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Company Calendar Last Earnings11/05/2021Today6/10/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees143Year FoundedN/APrice Target and Rating Average Stock Price Forecast$45.50 High Stock Price Forecast$56.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+110.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,920,000.00 Net Margins-4,090.69% Pretax Margin-4,090.69% Return on Equity-52.55% Return on Assets-47.61% Debt Debt-to-Equity RatioN/A Current Ratio11.60 Quick Ratio11.60 Sales & Book Value Annual Sales$4.74 million Price / Sales247.01 Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book3.69Miscellaneous Outstanding Shares54,030,000Free Float50,838,000Market Cap$1.17 billion OptionableNot Optionable Beta0.94 Key ExecutivesScott R. StruthersPresident, Chief Executive Officer & DirectorJeff E KnightChief Operating OfficerMarc J. S. WilsonChief Financial OfficerStephen F. BetzChief Scientific OfficerAlan Seth KrasnerChief Medical OfficerKey CompetitorsCTI BioPharmaNASDAQ:CTICStructure TherapeuticsNASDAQ:GPCROPKO HealthNASDAQ:OPKMannKindNASDAQ:MNKDAvadel PharmaceuticalsNASDAQ:AVDLView All CompetitorsInsiders & InstitutionsCoelho Rogerio VivaldiBought 5,000 shares on 6/8/2023Total: $110,300.00 ($22.06/share)JPMorgan Chase & Co.Bought 5,819 shares on 5/18/2023Ownership: 0.075%New York State Common Retirement FundSold 10,356 shares on 5/18/2023Ownership: 0.053%Geode Capital Management LLCBought 33,630 shares on 5/16/2023Ownership: 1.767%Altium Capital Management LPBought 100,000 shares on 5/16/2023Ownership: 0.185%View All Insider TransactionsView All Institutional Transactions CRNX Stock - Frequently Asked Questions Should I buy or sell Crinetics Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks. What is Crinetics Pharmaceuticals' stock price forecast for 2023? 5 brokerages have issued 12 month price targets for Crinetics Pharmaceuticals' stock. Their CRNX share price forecasts range from $35.00 to $56.00. On average, they expect the company's stock price to reach $45.50 in the next year. This suggests a possible upside of 110.0% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts. How have CRNX shares performed in 2023? Crinetics Pharmaceuticals' stock was trading at $18.30 at the beginning of the year. Since then, CRNX stock has increased by 18.4% and is now trading at $21.67. View the best growth stocks for 2023 here. When is Crinetics Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our CRNX earnings forecast. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Friday, November, 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.55% and a negative net margin of 4,090.69%. What ETFs hold Crinetics Pharmaceuticals' stock? ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Micro-Cap ETF (IWC) and iShares Biotechnology ETF (IBB). What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC). When did Crinetics Pharmaceuticals IPO? (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. What is Crinetics Pharmaceuticals' stock symbol? Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX." Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Wellington Management Group LLP (6.73%), Perceptive Advisors LLC (6.58%), State Street Corp (4.11%), Braidwell LP (3.74%) and First Light Asset Management LLC (3.00%). Insiders that own company stock include Ajay Madan, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Crinetics Pharmaceuticals' stock price today? One share of CRNX stock can currently be purchased for approximately $21.67. How much money does Crinetics Pharmaceuticals make? Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.17 billion and generates $4.74 million in revenue each year. The company earns $-163,920,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. How many employees does Crinetics Pharmaceuticals have? The company employs 143 workers across the globe. How can I contact Crinetics Pharmaceuticals? Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com. This page (NASDAQ:CRNX) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.